FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and may be used for treating dry age-related macular degeneration (dry ARMD). That is ensured by preparing a biocompatible prolonged release drug delivery system containing bevacizumab from 5 mcg to 20 mcg, and a carrier made of a polymer hyaluronic acid associated with bevacizumab administered into a vitreous body with using a 25-30-measuring syringe. In average, bevacizumab from 14 to 120 ng is released for 24 hours in the period of three to six months. The delivery system has a viscosity of 130,000 cPs to 300,000 cPs at the shear velocity of 0.1/second at 25°C.
EFFECT: using the given inventions enables treating dry ARMD with preventing or delaying wet ARMD.
5 cl, 1 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION | 2009 |
|
RU2668371C2 |
| APPLICATION OF ANTAGONIST VEGF IN TREATMENT OF CHORIORETINAL NEOVASCULAR DISTURBANCES AND DISORDERS OF PENETRATION IN PEDIATRIC PATIENTS | 2014 |
|
RU2676274C2 |
| PEPTIDES FOR INHIBITING ANGIOGENESIS | 2016 |
|
RU2708375C2 |
| INTRAOCULAR SYSTEMS OF SUSTAINED-RELEASE DRUG DELIVERY AND METHOD OF TREATING OPHTHALMIC DISEASES | 2010 |
|
RU2532333C2 |
| BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR LONG-TERM RELEASE OF PROTEIN | 2013 |
|
RU2676102C2 |
| METHOD OF TREATING ELEVATED INTRAOCULAR PRESSURE USING INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEM | 2014 |
|
RU2664686C2 |
| INTRAOCULAR DRUG DELIVERY SYSTEMS | 2007 |
|
RU2440102C2 |
| LIPOSOMAL PREPARATIONS | 2013 |
|
RU2817350C2 |
| LIPOSOME FORMULATIONS | 2013 |
|
RU2680096C2 |
| NANOSTRUCTURED COMPOSITIONS FOR DELIVERY OF SILIBININ AND OTHER ACTIVE INGREDIENTS FOR TREATING EYE DISEASES | 2015 |
|
RU2726193C2 |
